Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

Clinical trial NCT05136690 · COMPLETED

Trial details

NCT number: NCT05136690
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Cognitive Impairment Associated With Schizophrenia

Start date: 2022-04-27
Primary completion: 2022-09-23
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.